Influence of new dialysis solutions on outcome in patients treated with peritoneal dialysis;Einfluss neuer dialysatlösungen auf klinische ergebnisse bei peritonealdialyse-patienten

Wiener Klinische Wochenschrift, Supplement

Volumn 117, Issue 6, 2005, Pages 89-97

  Haag Weber, Marianne ^a  

^a Urologische Klinik   (Germany)

Author keywords

Amino acids; Biocompatibility; Glucose degradation products; Icodextrin; Peritoneal dialysis solutions

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; AMYLASE; CA 125 ANTIGEN; DIALYSIS FLUID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; GLUCOSE DEHYDROGENASE; GLUCOSE OXIDASE; GLUCOSE POLYMER; ICODEXTRIN; MALTOSE; OSMOTIC AGENT;

ACIDOSIS; BIOCOMPATIBILITY; DIALYSATE; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; FIBROSIS; HUMAN; INFLAMMATION; LONG TERM CARE; MORTALITY; NONHUMAN; PAIN; PERITONEAL DIALYSIS; PROGNOSIS; RAT STRAIN; REVIEW; SURVIVAL TIME; ULTRAFILTRATION;

CLINICAL TRIALS; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; OUTCOME ASSESSMENT (HEALTH CARE); PERITONEAL DIALYSIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 32144434056     PISSN: 03005178     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0484-y     Document Type: Review

References (72)

1. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al (2002) Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 113: 470-479
2. Krediet RT, van Westrhenen R, Zweers MM, Struijk DG (2002) Clinical advantages of new peritoneal dialysis solutions. Nephrol Dial Transplant 17 [Suppl 3]: 16-18
3. Wieczorowska-Tobis K, Brelinska R, Witowski J, Passlick-Deetjen J, Schaub TP, Schilling H, et al (2004) Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 24: 48-57
4. Wieslander A, Linden T, Musi B, Carlsson O, Deppisch R (2000) Biological significance of reducing glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 20 [Suppl 5]: S23-S27
5. Tamura M, Osajima A, Nakayamada S, Anai H, Kabashima N, Kanagae K, et al (2003) High glucose levels inhibit focal adhesion kinase-mediated healing of rat peritoneal mesothelial cells. Kidney Int 63: 722-731
6. Fusshöller A, Baehr J, Grabensee B, Plum J (2005) Biocompatibility of a bicarbonate/lactate-buffered PD fluid tested with a double-chamber cell culture system. Perit Dial Int 25: 387-393
7. Plum J, Razeghi P, Lordnejad RM, Perniok A, Fleisch M, Fusshöller A, et al (2001) Peritoneal dialysis fluids with a physiologic pH based on either lactate or bicarbonate buffer - effects on human mesothelial cells. Am J Kidney Dis 38: 867-875
8. Ha H, Cha MK Choi HN, Lee HB (2002) Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 22: 171-177
9. Boulanger E, Wautier MP, Gane P, Mariette CD, Evuyst O, Wautier JL (2004) The triggering of human peritoneal mesothel cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 19: 2208-2216
10. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N, Bicarbonate/Lactate Study Group (2001) Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 21 [Suppl 3]: S102-S107
11. Park SH, Lee EG, Kim IS, Kim YJ, Cho DK, Kim YL (2004) Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat. Perit Dial Int 24: 115-122
12. Jones S, Holmes CJ, Mackenzie RK, Stead R, Coles GA, Williams JD, et al (2002) Continuous dialysis with bicarbonate/lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function. J Am Soc Nephrol 13: 97-103
13. Catalan PM, Santamaria B, Reyero A, Ortiz A, Egido J, Ortiz A (2005) 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int 68: 1303-1311
14. Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire NH (2002) Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration and glucose degradation products. J Am Soc Nephrol 13: 480-489
15. Zeier M, Schwenger V, Deppisch R, Haug U, Wiegel K, Bahner U, et al (2003) Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63: 298-305
16. Erixon M, Linden T, Kjellstrand P, Carlsson O, Ernebrant M, Forsbäck G, et al (2004) PD fluids contain high concentrations of cytotoxic GDPs directly after sterilisation. Perit Dial Int 24: 392-398
17. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al (1997) Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 51: 182-186
18. Nakamura S, Tobita K, Tachikawa T, Akamatsu S, Ohno Y, Kan A, et al (2003) Immunohistochemical detection of an AGE, a ligand for macrophage receptor in peritoneum of CAPD patients. Kidney Int 63 [Suppl 84]: S152-S157
19. Williams JD, Craig KJ, Topley N, Williams GT (2003) Peritoneal dialysis: changes in the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney Int 63 [Suppl 84]: S158-S161
20. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al (1999) Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 14: 1541-1549
21. Plum J, Hermann S, Fusshöller A, Schoenicke G, Donner A, Röhrborn A, et al (2001) Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport. Kidney Int 59 [Suppl 78]: S42-S47
22. Mortier S, Faict D, Schalwijk CG, Lameire NH, De Vriese AS (2004) Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 66: 1257-1265
23. Mortier S, Faict D, Lameire NH, De Vriese AS (2005) Benefits of switching form a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 67: 1559-1565
24. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al (2001) Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59: 348-357
25. Fußhöller A, Plail M, Grabensee B, Plum J (2004) Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 19: 2101-2106
26. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, et al (2003) Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 14: 2632-2638
27. Tauer A, Zhang X, Schaub P, Zimmeck T, Niwa T, Passlick-Deetjen J, et al (2003) Formation of advanced glycation end products during CAPD. Am J Kidney Dis 41 [Suppl 1]: S57-S60
28. Williams JD, Topley NT, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al (2004) The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66: 408-418
29. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al (2005) Superior patient survival for continuous ambulatory peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int 25: 248-255
30. Kopple JD, Bernhard D, Messana J, Swartz R, Bergström J, Lindholm B, et al (1995) Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 47: 1148-1157
31. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, et al (1998) Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 32: 761-769
32. Taylor GS, Patel V, Spencer S, Fluck RJ, McIntyre CW (2002) Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol 58: 445-450
33. Li FK, Chan LYY, Woo JCY, Ho SKN, Lo WK, Lai KN, et al (2003) A 3-year prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 42: 173-183
34. Delarue J, Maingourd C (2001) Acute metabolic effects of dialysis fluids during CAPD. Am J Kidney Dis 37 [Suppl 2]: S103-S107
35. Wolfson M, Jones M (1999) Intraperitoneal nutrition. Am J Kidney Dis 33: 203-204
36. Garibotto G, Sofia A, Canepa A, Saffioti S, Sacco P, Sala MR, et al (2001) Acute effects of peritoneal dialysis with dialysates containing dextrose and amino acids on muscle protein turnover in patients with chronic renal failure. J Am Soc Nephrol 12: 557-567
37. Canepa A, Carrea A, Menoni S, Verrina E, Trivelli A, Gusmano R, et al (2001) Acute effects of simultaneous intraperitoneal infusion of glucose and amino acids. Kidney Int 59: 1967-1973
38. Tjiong HL, Van den Berg JW, Wattimena JL, Rietveld T, Van Dijk LJ, Van der Wiel AM, et al (2005) Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patiens on automated peritoneal dialysis. J Am Soc Nephrol 16: 1486-1493
39. Jones MR, Gehr TW, Burkart JM, Hamburger RJ, Kraus AP, Piraino BM, et al (1998) Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution. Perit Dial Int 18: 210-216
40. Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F (1989) CAPD with amino acid dialysis solution: a long-term cross-over study. Kidney Int 35: 1189-1194
41. Young GA, Dibble JB, Taylor AE, Kendall S, Brownjohn AM (1989) A longitudinal study of the effects of amino acid-based CAPD fluid on amino acid retention and protein losses. Nephrol Dial Transplant 4: 900-905
42. Brulez HF, van Guldener C, Donker AJ, ter Wee PM (1999) The impact of amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 14: 154-159
43. Misra M, Reaveley DA, Ashworth J, Muller B, Seed M, Brown EA (1997) Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 17: 279-286.
44. Marshall J, Jennings P, Scott A, Fluck RJ, Mc Intyre CW (2003) Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system. Kidney Int 64: 1480-1486
45. Ueda Y, Miyata T, Goffin E, Yoshino A, Inagi R, Ishibashi Y, et al (2000) Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluid. Kidney Int 58: 2518-2524
46. Zareie M, van Lambalgen AA, ter Wee PM, Hekking LH, Keuning ED, Schade-Eestermans IL, et al (2005) Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. Perit Dial Int 25: 58-67
47. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS (2004) Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 66: 1257-1265.
48. Reimann D, Dachs D, Meye C, Gross P (2004) Amino acid-based dialysis solution stimulates mesothelial nitric oxide production. Perit Dial Int 24: 378-384
49. Douma CE, de Waart DR, Struijk DG, Krediet RT (1996) Effect of amino based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential role for nitric oxide? Clin Nephrol 45: 295-302
50. Vychytil A, Födinger M, Pleiner J, Müllner M, Konner P, Skoupy S, et al (2003) Acute effect of amino acid peritoneal dialysis solution on vascular function. Am J Clin Nutr 78: 1039-1045
51. Mujais S, Vonesh E (2002) Profiling of peritoneal ultrafiltration. Kidney Int 62 [Suppl 81]: S17-S22
52. Rippe B, Levin L (2000) Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int 57: 2546-2556
53. Wiggins KJ, Rumpsfeld M, Blizzard S, Johnson DW (2005) Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure. Nephrology 10: 33-36
54. Krediet R, Mujais S (2002) Use of icodextrin in high transport ultrafiltration failure. Kidney Int 62 [Suppl 81]: S53-S61
55. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al (2005) Superiority of icodextrin compared with 4,25% dextrose for peritoneal ultrafiltration. J. Am Soc Nephrol 16: 546-554
56. Garcia-Lopez E, Anderstam B, Heimburger O, Amici G, Werynski A, Lindholm B (2005) Determination of high and low mlecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients. Perit Dial Int 25: 181-191
57. Gokal R, Moberly J, Lindholm B, Mujais S (2002) Metabolic and laboratory effects of icodextrin. Kidney Int 62 [Suppl 81]: S62-S71
58. Gradden CW, Ahmad R, Bell GM (2001) Peritoneal dialysis: new developments and new problems. Diabet Med 18: 360-363
59. Wens R, Tamine M, Devriendt J, Collart F, Broeders N, Mestrez F, et al (1998) A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer. Perit Dial Int 18: 603-609
60. Schoenicke G, Grabensee B, Plum J (2002) Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant 17: 1988-1992
61. Burke RA, Hughes G, Moberly JB (1999) Lack of interference of icodextrin on creatinine measurements. Adv Perit Dial 15: 234-237
62. Amici G, Orrasch M, Da Rin G, Bocci C (2001) Hyper-insulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 17: 80-83
63. Mistry CD, Gokal R, Peers E, MIDAS-Study Group (1994) A randomized multicenter clinical trial comparing iso-osmolar icodextrin with hyperosmolar glucose solution in CAPD. Kidney Int 46: 496-503
64. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R (2001) Effects of peritoneal dialysis with an overnight icodextrin-dwell on parameters of glucose and lipid metabolism. Perit Dial Int 21: 275-281
65. Sisca S, Maggiore U (2002) Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients. Perit Dial Int 22: 727-729
66. Wolfson M, Ogring F, Mujais S (2002) Review of clinical trial experience with icodextrin. Kidney Int [Suppl 81]: S46-S52
67. Plum J, Gentile G, Verger C, Brunkhorst R, Bahner U, Faller B, et al (2002) Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 39: 862-871
68. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al (2003) Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 14: 2338-2344
69. Konings CJAM, Kooman JP, Schonck M, Gladziwa U, Wirtz J, Van den Wall Bake W, et al (2003) Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 63: 1556-1563
70. Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW (2005) Hypertonic glucose based peritoneal dialysate is associated with high blood pressure and adverse hemodynamics as compared with icodextrin. Nephrol Dial Transplant 20: 1848-1853
71. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, et al (2005) Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 67: 1609-1615
72. Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier MA, et al (2005) Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 365: 588-594